Neurocrine Biosciences 的盈利预期和股票评级受到分析师的提振。 Neurocrine Biosciences sees earnings estimates and stock ratings boosted by analysts.

内分泌生物科学是一家以神经及相关疾病为重点的制药公司,其2027财政年度和2028财政年度的收入估计数分别由Wedbush提高到每股14.46美元和17.74美元。 Neurocrine Biosciences, a pharmaceutical company focusing on neurological and related disorders, has seen its FY2027 and FY2028 earnings estimates raised by Wedbush to $14.46 and $17.74 per share, respectively. 股票目前有"超强"评级, 目标价148美元. The stock currently has an "Outperform" rating and a $148 target price from Wedbush. 其他分析家也发表了正面报告,导致达成“机动购买”共识,平均目标价格为166.29美元。 Other analysts also issued positive reports, leading to an overall "Moderate Buy" consensus and an average target price of $166.29.